DNMT1 and acute myeloid leukemia: The combination of immune-checkpoint inhibition and DNMT and/or HDAC inhibition is also being tested in numerous clinical trials for a range of solid tumors, myelodysplastic syndrome, and/or AML which are listed below (Table 2).